**Supplementary Table 4.** Odds ratios for the hepatic steatosis stages according to u-NCR in insulin users (*n* = 300)

| Model | Hepatic steatosis stage 1 (S1) | Hepatic steatosis stage 2 (S2) | Hepatic steatosis stage 3 (S3) |
|-------|-------------------------------|--------------------------------|--------------------------------|
|       | aOR (95% CI) | P value | aOR (95% CI) | P value | aOR (95% CI) | P value |
| 1     | 1.26 (0.70–2.24) | 0.441 | 0.74 (0.43–1.25) | 0.260 | 0.78 (0.46–1.33) | 0.362 |
| 2     | 1.39 (0.76–2.52) | 0.282 | 0.77 (0.44–1.36) | 0.372 | 0.83 (0.48–1.43) | 0.503 |
| 3     | 1.46 (0.76–2.79) | 0.263 | 0.86 (0.48–1.54) | 0.613 | 0.77 (0.43–1.38) | 0.372 |
| 4     | 1.84 (0.90–3.74) | 0.093 | 0.56 (0.28–1.13) | 0.110 | 0.57 (0.29–1.14) | 0.110 |

Model 1 was adjusted for age, male sex, body mass index, and duration of diabetes; Model 2 adjusted for Model 1 parameters plus hypertension, lipid medication; Model 3 adjusted for Model 2 parameters plus triglyceride, alanine aminotransferase; Model 4 adjusted for Model 3 parameters plus glycosylated hemoglobin, insulin.

u-NCR, urinary *N*-acetyl-β-D-glucosaminidase to creatinine ratio; aOR, adjusted odds ratio; CI, confidence interval.